ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas M. Egan
Frank C. Detterbeck
Michael R. Mill
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Egan, T. M.
Right arrow Articles by Paradowski, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Egan, T. M.
Right arrow Articles by Paradowski, L. J.

Ann Thorac Surg 1998;66:337-346
© 1998 The Society of Thoracic Surgeons

Original articles: general thoracic

Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group

Thomas M. Egan, MDa, Frank C. Detterbeck, MDa, Michael R. Mill, MDa, Kristi K. Gott, RNa, Jean B. Rea, RNa, Judy McSweeney, RNa, Robert M. Aris, MDa, Linda J. Paradowski, MDa

a Divisions of Cardiothoracic Surgery and Pulmonary Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Address reprint requests to Dr Egan, University of North Carolina at Chapel Hill, 108 Burnett-Womack Bldg, CB 7065, Chapel Hill, NC 27599-7065

Presented at the Forty-fourth Annual Meeting of the Southern Thoracic Surgical Society, Naples, FL, Nov 6–8, 1997.

Background. The purpose of this study was to review our experience with lung transplantation in patients with end-stage cystic fibrosis.

Methods. Eight-two patients with cystic fibrosis have undergone bilateral lung transplantation (n = 76) or bilateral lower lobe transplantation (n = 6) since October 1990.

Results. Actuarial survival for the entire cohort is 79% at 1 year and 57% at 5 years. The development of bronchiolitis obliterans syndrome is the leading cause of death after the first year. Freedom from bronchiolitis obliterans syndrome is 84% at 1 year and 51% at 3 years. Pulmonary function tests improve dramatically in recipients. There was no association between death within 1 year and recipient age, weight, graft ischemic time, cytomegalovirus seronegativity, or the presence of panresistant organisms. Similarly, there was no association between the development of bronchiolitis obliterans syndrome within 2 years and ischemic time, number of rejection episodes, cytomegalovirus seronegativity, or the presence of panresistant organisms.

Conclusions. Despite their poor nutritional status and the presence of multiply resistant organisms, patients with cystic fibrosis can undergo bilateral lung transplantation with acceptable morbidity and mortality.




This article has been cited by other articles:


Home page
 ThoraxHome page
G Meachery, A De Soyza, A Nicholson, G Parry, A Hasan, K Tocewicz, T Pillay, S Clark, J L Lordan, S Schueler, et al.
Outcomes of lung transplantation for cystic fibrosis in a large UK cohort
Thorax, August 1, 2008; 63(8): 725 - 731.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
W Chalermskulrat, N Sood, I P Neuringer, T M Hecker, L Chang, M P Rivera, L J Paradowski, and R M Aris
Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation
Thorax, June 1, 2006; 61(6): 507 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. E. Reed
General thoracic surgery and the Southern Thoracic Surgical Association: the second 25 years
Ann. Thorac. Surg., November 1, 2003; 76(90050): S14 - 16.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T.M. Egan, F.C. Detterbeck, M.R. Mill, M.S. Bleiweis, R. Aris, L. Paradowski, G. Retsch-Bogart, and B.S. Mueller
Long term results of lung transplantation for cystic fibrosis
Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 602 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
L. A. Vricella, J. M. Karamichalis, S. Ahmad, R. C. Robbins, R. I. Whyte, and B. A. Reitz
Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the stanford experience
Ann. Thorac. Surg., July 1, 2002; 74(1): 13 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. ARIS, J. C. ROUTH, J. J. LIPUMA, D. G. HEATH, and P. H. GILLIGAN
Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex . Survival Linked to Genomovar Type
Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2102 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Date, M. Yamashita, I. Nagahiro, M. Aoe, A. Andou, and N. Shimizu
Living-donor lobar lung transplantation for primary ciliary dyskinesia
Ann. Thorac. Surg., June 1, 2001; 71(6): 2008 - 2009.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1998 by The Society of Thoracic Surgeons.